Amwill Health

Who are the top shareholders of the Amwill?

The top shareholders of Amwill include promoter Anand Gandhi with 31.64%, two Foreign Institutional Investors holding 1.16%, and public shareholder Varun Krishnavtar Kabra with 2.86%. Individual investors own 21.14% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Amwill include the promoters, who hold the majority of the shares. The promoter with the highest holding is Anand Gandhi, owning 31.64% of the company. Additionally, there are two Foreign Institutional Investors (FIIs) that collectively hold 1.16%. The highest public shareholder is Varun Krishnavtar Kabra, with a stake of 2.86%. Individual investors also hold a significant portion, accounting for 21.14% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Has Amwill declared dividend?

No Dividend History Available

Who are the peers of the Amwill?

Amwill's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Management risk varies from excellent to average among peers, with Divi's Lab showing the highest 1-year return at 51.88% and Smruthi Organic the lowest at -22.54%.

Peers: The peers of Amwill are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Krebs Biochem, Auro Labs., Bal Pharma, Smruthi Organic, and Aarey Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill, Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Auro Labs., and Smruthi Organic, while Good management risk is found at Divi's Lab., Torrent Pharma, Bal Pharma, and Aarey Drugs. Average management risk is noted at Bal Pharma, and the rest have either below average or do not qualify. Growth is excellent at Amwill, Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, Auro Labs., and Smruthi Organic. Average growth is noted at Bal Pharma, and the rest do not qualify.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.88%, while Smruthi Organic has the lowest at -22.54%. Amwill's 1-year return is not available for comparison. Additionally, Krebs Biochem and Smruthi Organic have negative six-month returns.

What does Amwill Health do?

Amwill Health Care Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, was incorporated in 2017 and became a Public Limited Company in 2024. It has a market cap of INR 133 Cr, with a P/E ratio of 13.00 and a return on equity of 62.53%.

Overview:<BR>Amwill Health Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Amwill Health Care Ltd was originally incorporated on August 21, 2017, under the name 'Amwill Health Care Private Limited'. The company transitioned to a Public Limited Company, receiving a fresh Certificate of Incorporation on January 25, 2024, with the name change to 'Amwill Health Care Limited'. Revenue and profit data are not available for any specific quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 133 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.19<BR>Return on Equity: 62.53%<BR>Price to Book: 7.75<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

How big is Amwill Health?

As of 24th July, Amwill Health Care Ltd has a market capitalization of 134.00 Cr, classified as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. As of March 2025, Shareholder's Funds are 69.22 Cr and Total Assets are 71.26 Cr.

As of 24th July, <BR><BR>Market Cap: Amwill Health Care Ltd has a market capitalization of 134.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 69.22 Cr and Total Assets at 71.26 Cr.

How has been the historical performance of Amwill Health?

Amwill Health's historical performance shows fluctuating financial metrics, with net sales rising to 43.95 Cr in Mar'24 before declining to 40.58 Cr in Mar'25. Despite growth in total assets and improved cash flow, profitability metrics such as operating profit and profit after tax decreased in the latest fiscal year.

Answer:<BR>The historical performance of Amwill Health shows a fluctuating trend in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Amwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, before declining to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising to 43.95 Cr in Mar'24 and then decreasing to 40.58 Cr in Mar'25. The total expenditure also rose from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit, excluding other income, peaked at 16.67 Cr in Mar'24 but fell to 11.65 Cr in Mar'25. Profit before tax showed a similar decline from 16.76 Cr in Mar'24 to 11.90 Cr in Mar'25, while profit after tax decreased from 12.50 Cr to 10.73 Cr in the same period. The company's total assets grew significantly from 12.29 Cr in Mar'23 to 71.26 Cr in Mar'25, indicating a strong increase in shareholder's funds, which rose to 69.22 Cr by Mar'25. Cash flow from operating activities improved to 5.00 Cr in Mar'25, contrasting with a negative cash flow of -3.00 Cr in Mar'24. Overall, while Amwill Health experienced growth in assets and operating cash flow, its profitability metrics showed a decline in the most recent fiscal year.

Is Amwill Health overvalued or undervalued?

As of November 7, 2025, Amwill Health is considered undervalued with a PE ratio of 9.06 and strong return metrics, making it an attractive investment compared to peers like Sun Pharma and Dr Reddy's Labs.

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 9.06, an EV to EBIT of 7.64, and an EV to EBITDA of 7.34. These ratios suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector.<BR><BR>In comparison, Sun Pharma is considered expensive with a PE ratio of 35.17, while Dr Reddy's Labs is attractive with a PE ratio of 17.43. This peer comparison highlights Amwill Health's favorable valuation position. Additionally, the company's return metrics are strong, with a ROCE of 18.23% and a ROE of 14.68%, further supporting the undervaluation narrative. Despite recent stock performance lagging behind the Sensex, the overall valuation suggests a compelling investment opportunity in Amwill Health.

When is the next results date for Amwill Health Care Ltd?

The next results date for Amwill Health Care Ltd is 30 May 2026.

The next results date for Amwill Health Care Ltd is scheduled for 30 May 2026.

Why is Amwill Health Care Ltd falling/rising?

As of 02-Jun, Amwill Health Care Ltd's stock price is rising to Rs 36.04, up 4.98%, supported by an 11.30% gain over the past week. Despite positive short-term momentum, declining investor participation raises concerns about sustained interest.

As of 02-Jun, Amwill Health Care Ltd's stock price is rising, currently at Rs 36.04, reflecting an increase of Rs 1.71 or 4.98%. This upward movement is supported by a strong performance over the past week, where the stock has gained 11.30%, significantly outperforming the Sensex, which has declined by 1.79% during the same period. Additionally, the stock has shown consistent gains over the last three days, accumulating a total return of 11.51%. <BR><BR>Today, the stock opened with a notable gap up of 4.86%, reaching an intraday high of Rs 36.04. Despite trading within a narrow range of Rs 0.04, the stock's current price is above its 5-day, 20-day, and 50-day moving averages, indicating a short-term bullish trend. However, it is important to note that the stock is still trading below its 100-day and 200-day moving averages, suggesting that while there is recent positive momentum, it has not yet regained its longer-term strength.<BR><BR>Despite the positive price movement, there is a decline in investor participation, with delivery volume dropping by 50% compared to the 5-day average. This could indicate a potential concern regarding sustained interest in the stock. Nevertheless, the current liquidity remains adequate for trading. Overall, the combination of recent gains, positive short-term performance, and a significant gap up today contributes to the stock's rising price.

Which are the latest news on Amwill Health?